# Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)

> **NCT00961376** · PHASE2 · TERMINATED · sponsor: **Providence Health & Services** · enrollment: 5 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** PBMC re-infusion
- **BIOLOGICAL:** CD25 depletion

## Key facts

- **NCT ID:** NCT00961376
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-02-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** PI Discretion
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961376, "Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00961376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*